|
|
|
|
|
| Effects of intracoronary tirofiban plus short duration of infusion administration in patients with
ST- segment elevation myocardial infarction after primary percutaneous coronary intervention |
| SHANG Zhuo, LUO Wei- shu, GUAN Jie, SHI Jun, DONG Li- hong, ZHENG Xiao- qun |
| Department of Cardiology, Dalian Municipal Center Hospital，Dalian 116033, China |
|
|
|
|
Abstract Objective To explore the efficacy and safety of intracoronary tirofiban plus short duration of infusion administration in patients with ST-segment elevation myocardial infarction (STEMI) after primary percutaneous coronary intervention (PCI). Methods According to duration of infusion tirofiban after primary PCI, 315 patients with STEMI were divided into routine duration group (n＝164, infusion tirofiban 18~24 h ) and short duration group (n＝151, infusion tirofiban＜18 h). The ST-segment resolution (STR), thrombolysis in myocardial infarction (TIMI) flow grade (TFG), corrected TIMI frame
count (cTFC), cardiac function performance parameters, major adverse cardiac events (MACE), bleeding
events and thrombocytopenia were calculated and analyzed after completion of primary PCI. Results
There was no significant difference between the two groups with regard to cardiac function performance parameters, STR (P＝0.885), TFG (P＝0.751), cTFC (P＝0.222), thrombocytopenia (P＝0.062) and MACE (P＝0.186). Bleeding events including serious bleeding event in short duration group were less
than those in routine duration group. Conclusion The intracoronary tirofiban plus short duration of infusion strategy, which is associated with a better safety demonstrated by reducing bleeding events, is an alternative regimen for patients with STEMI undergoing primary PCI.
|
|
Received: 23 September 2015
|
|
Corresponding Authors:
ZHENG Xiao-qun, E-mail: centerhosp_cariol@163.com
|
|
|
|
| [1] Hess CN, Schulte PJ, Laneway LK, et al. Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high- risk patients with non- ST- segment elevation acute coronary syndrome: insights from EARLY ACS[J]. Eur Heart J Acute Cardiovasc Care, 2013, 2 (3)：246-255.
[2] Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium[J]. Circulation, 2011,123 (23) : 2736-2747.
[3] 中华医学会心血管病学分会;中华心血管病杂志编辑委员会. 急性ST 段抬高型心肌梗死诊断和治疗指南[S]. 中华心血管病杂志, 2015, 43(5): 380-393.
[4] Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT- OASIS 7): a randomised factorial trial [J]. Lancet, 2010, 376 (9748): 1233-1243.
[5] Schneider DJ. Anti-platelet therapy: glycoprotein IIb-IIIa antagonists [J]. Br J Clin Pharmacol, 2011, 72 (4): 672-682.
[6] 王勇，商德亚．急性下壁心肌梗死应用Diver CE 血栓抽吸导管 联合盐酸替罗非班的临床疗效研究 [J]．中国急救医学, 2009,29 (9)：789-792．
[7] 张优，高传玉，刘洪智，等．早期应用盐酸替罗非班对行介入治疗的中高危急性冠状动脉综合征患者血小板聚集率和临床结果的影响[J]．中国急救医学, 2010, 30（1）：69-72．
[8] 卢竞前，李易，杨锋，等．盐酸替罗非班联合不同时间介入治疗对急性ST 段抬高型心肌梗死的影响[J]．中国急救医学, 2009,29 (6)：509-511．
[9 隋立有，梁冬梅，沈杰，等．盐酸替罗非班治疗ST 段抬高急性心肌梗死冠状动脉再通患者的临床特征及预后分析[J]．中国急
救医学, 2010,29 (4)：312-315．
[10] Xu HP, Liu CM, Zhang WW. Effect of intracoronary tirofiban on platelet alpha- granule membrane protein and myocardial perfusion level during emergency percutaneous coronary intervention[J]. Genet Mol Res, 2014, 13 (4): 9599-9605. |
|
|
|
Address: 1 North 2nd Street,
Zhongguancun, 
